Option Care Health, Inc. $OPCH Shares Acquired by Advantage Alpha Capital Partners LP

Key Points

• Advantage Alpha Capital Partners LP has increased its stake in Option Care Health by 78.7%, making the stock its fourth largest position.
• Option Care Health reported a 15.4% increase in quarterly revenue year-over-year, with earnings per share beating analyst estimates.
• Multiple brokerages have updated their target prices for Option Care Health, with JMP Securities increasing it to $38.00 and UBS Group upgrading it to a "buy" rating.

Advantage Alpha Capital Partners LP raised its position in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 78.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 214,619 shares of the company's stock after acquiring an additional 94,528 shares during the quarter. Option Care Health makes up about 1.8% of Advantage Alpha Capital Partners LP's holdings, making the stock its 4th largest holding. Advantage Alpha Capital Partners LP owned 0.13% of Option Care Health worth $7,501,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Andina Capital Management LLC acquired a new stake in shares of Option Care Health in the first quarter valued at approximately $513,000. Fuller & Thaler Asset Management Inc. increased its stake in Option Care Health by 30.8% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 4,204,481 shares of the company's stock worth $146,947,000 after acquiring an additional 989,048 shares during the last quarter. Brooklyn Investment Group increased its stake in Option Care Health by 186.6% during the first quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock worth $42,000 after acquiring an additional 780 shares during the last quarter. Prospector Partners LLC increased its stake in Option Care Health by 22.9% during the first quarter. Prospector Partners LLC now owns 111,200 shares of the company's stock worth $3,886,000 after acquiring an additional 20,700 shares during the last quarter. Finally, Versor Investments LP increased its stake in Option Care Health by 191.8% during the first quarter. Versor Investments LP now owns 56,900 shares of the company's stock worth $1,989,000 after acquiring an additional 37,400 shares during the last quarter. Institutional investors and hedge funds own 98.05% of the company's stock.

Option Care Health Stock Performance

Shares of OPCH stock traded up $0.55 during trading hours on Wednesday, reaching $28.47. 769,994 shares of the company's stock were exchanged, compared to its average volume of 1,851,992. The company has a market cap of $4.62 billion, a P/E ratio of 22.78, a price-to-earnings-growth ratio of 1.71 and a beta of 0.79. The company's 50 day moving average is $29.77 and its two-hundred day moving average is $31.71. Option Care Health, Inc. has a 1 year low of $21.39 and a 1 year high of $35.53. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.00.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.40 by $0.01. The business had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The company's revenue was up 15.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.30 EPS. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. Equities research analysts anticipate that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. UBS Group upgraded Option Care Health from a "neutral" rating to a "buy" rating and raised their price target for the stock from $38.00 to $40.00 in a research report on Wednesday, April 30th. Citigroup restated an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. JMP Securities lifted their target price on Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a report on Thursday, July 31st. Finally, Barrington Research reiterated an "outperform" rating and issued a $38.00 target price on shares of Option Care Health in a report on Thursday, July 10th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $35.75.

Insider Buying and Selling at Option Care Health

In related news, Director Timothy P. Sullivan purchased 20,000 shares of the company's stock in a transaction on Thursday, August 21st. The stock was bought at an average price of $27.51 per share, with a total value of $550,200.00. Following the completion of the transaction, the director owned 49,229 shares of the company's stock, valued at approximately $1,354,289.79. This represents a 68.43% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were bought at an average cost of $27.15 per share, with a total value of $977,400.00. Following the transaction, the director directly owned 375,390 shares of the company's stock, valued at $10,191,838.50. This represents a 10.61% increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.64% of the company's stock.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.